In one study, Lambein et al. (37) re-performed HER2 IHC evaluation for a set of 150 consecutive cases of invasive breast cancer that had been previously designated HER2-IHC-negative (0+ or 1+) based on IHC performed at a local laboratory. The gene discussed is ERBB2; the disease is invasive breast carcinoma.